In this week's video, Dr. Brian Durie discusses selinexor, a novel, orally administered drug that is currently ongoing clinical trials.

Bottom Line:

Selinexor is a promising new type of drug that can make a difference for myeloma patients.

Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.